Covers clinically relevant biomarkers, including TMB, MSI status, and PD-L1.1
NSCLC guideline-recommended genes are shown in bold.
MSI, microsatellite instability status; NSCLC, non-small cell lung cancer;
PD-L1, programmed cell death ligand 1; TMB, tumor mutation burden.
*Includes TERT promoter region.¹
†Guardant360 TissueNext PD-L1 test powered by Guardant Galaxy is now validated for multiple tumor types, including breast, colorectal, gastric, hepatobiliary, lung, pancreatic, prostate, and urothelial cancers. Some cases may require conventional determination of PD-L1 status without AI.1-5
Home Guardant Infinity™ for HCPs Treatment Selection Monitoring and MRD Assessment Guardant Infinity™ for BioPharma